MARSEILLE, France, April 15, 2025 /PRNewswire/ — Volta Medical, a pioneering health technology company focused on developing artificial intelligence (AI) solutions for electrophysiologists, is set to present significant findings at the Heart Rhythm Society 2025 meeting, scheduled to take place in San Diego from April 24 to 27.
These presentations will include a special Rhythm Theater session featuring expert panelists, moderated by Dr. Vivek Reddy of The Mount Sinai Hospital.
Dr. Clément Bars, co-founder of Volta Medical, will share additional findings from the landmark TAILORED-AF clinical trial, which has expanded the understanding of treatment options for patients suffering from atrial fibrillation (AF).
Meanwhile, Dr. John Hummel, an esteemed electrophysiologist at Ohio State University Wexner Medical Center and the principal investigator for the RESTART trial, will present the initial outcomes of this study, which focuses on underserved patients requiring re-ablation.
Volta Medical is excited to showcase its latest clinical and technological advancements at Heart Rhythm 2025 through the session titled “AI-Driven Innovation in AF Ablation Procedures.”
The expert panel discussing the role of AI in complex AF cases will also include Dr. Tina Baykaner from Stanford Medicine, Dr. Paul Zei of Brigham and Women’s Hospital, and Dr. Benjamin D’Souza of Penn Presbyterian Medical Center.
Dr. Hummel’s presentation will detail acute and long-term outcomes from the RESTART trial, an international multicenter, non-randomized interventional study aimed at evaluating outcomes in recurrent-AF patients, particularly those who have failed previous ablations.
By utilizing Volta AI-guided ablation, the trial aims to assess the potential for patients to be AF-free without the need for antiarrhythmic drugs twelve months post-procedure.
A significant focus of the RESTART trial is on patients whose previous pulmonary vein isolation (PVI) remains intact, a group often posed with challenging treatment scenarios.
During his presentation, Dr. Clément Bars will delve into the findings of the TAILORED-AF trial, a transatlantic, randomized controlled study that has demonstrated the superior effectiveness of Volta’s AI-guided strategy coupled with PVI compared to PVI alone.
He will provide insights into the utilization of artificial intelligence throughout the trial process, an overview of the evolution of the Volta AF-Xplorer™ technology, and an explanation of how the AF-Xplorer platform operates.
These findings underscore Volta’s innovative approach to treating a patient population that is often overlooked by conventional ablation methods.
Volta Medical will also have a booth at the conference (#1511), where attendees can witness live demonstrations of the AF-Xplorer.
This AI companion is designed to identify spatio-temporal dispersed electrograms (EGMs), aiming to assist in clinical decision-making during complex ablations.
The AF-Xplorer signifies a significant leap forward in the scalable, data-driven treatment of persistent atrial fibrillation, supporting Volta’s growth in the vast, global electrophysiology market.
Atrial fibrillation is recognized by the American Heart Association (AHA) as a quivering or irregular heartbeat that can have serious health consequences, including blood clots, strokes, heart failure, and other heart-related complications.
According to estimates, around 33 million patients worldwide are currently affected by AF.
Despite the fact that untreated AF can double the risk of heart-related deaths and escalate the stroke risk five-fold, many individuals remain unaware of the serious implications of this condition.
Volta Medical is dedicated to developing artificial intelligence software solutions that assist cardiac electrophysiologists during arrhythmia treatment procedures to enhance clinical outcomes for patients.
Founded in 2016 by three physicians and a data scientist in Marseille, France, Volta Medical aims to improve cardiac arrhythmia management through cutting-edge, data-driven medical devices derived from extensive databases of procedural data.
The Volta AF-Xplorer is engineered for versatility and has been demonstrated to work seamlessly with popular AF mapping and recording systems, in addition to the most common ablation modalities.
With U.S. FDA 510(k) clearance and European CE Mark approval, the AF-Xplorer represents a significant advancement in the treatment of atrial fibrillation.
Moreover, Volta Medical has initiated a therapy awareness program called AI for Persistent AF Care, specifically designed to educate the underserved AF patient community.
For more information, visit www.aiforafib.com.
image source from：https://www.biospace.com/press-releases/volta-medical-announces-presentations-at-heart-rhythm-society-2025-in-san-diego-ca-usa
